Replies to post #251450 on Innovation Pharmaceuticals Inc (IPIX)

[Amatuer17]

The EOP2 meeting - one example we have is GALT

on March 29th they announced FDA meeting.
On May 14th they announced that FDA meeting went well, they are going with P3 but FDA did not give them.

So they did not wait for the FDA minutes to be piblished before issuing the PR- looks like they announced possibly same week

May 14 - https://seekingalpha.com/pr/17181538

Mar 29 - “• Galectin (GALT +27%) updated investors earlier today on expected key milestones this year:
• It will meet with the FDA in early May to present results from the Phase 2b NASH-CX study of lead candidate GR-MD-02 that missed the primary endpoint but did show a promising treatment effect in a subset of NASH patients (without esophageal varices). The objective is to clarify the Phase 3 program.
• It has filed a request with the FDA seeking Breakthrough Therapy status for GR-MD-02 for the treatment of NASH cirrhosis without esophageal varices (dilated veins in the esophagus due to portal hypertension).”

[bradfordbros]

You conveniently left out the bits that showed the naivety of the poster and his/her trashing the Company.